Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Make a choice that matters
The best care starts with the best information
Registration is open for the Division Directors and Program Directors Conference March 8 - 9, 2019.
The ACR is your source for advocacy news impacting your practice, patients, and the rheumatology subspecialty. In addition to staying on top of ever changing policies and political landscapes for our members, we are often invited to give statements, provide comments, or work with lawmakers to promote new policies.
The purpose of this message is to provide information about the Trump administration’s recent announcement about Medicare Part B drugs and ask for your feedback on the proposal.
On October 25, 2018 the Centers for Medicare & Medicaid Services (CMS) released an advance notice of proposed rulemaking (ANPRM) seeking feedback on a potential drug pricing model called the International Pricing Index (IPI) model. This comment solicitation is in alignment with President Trump’s blueprint to lower drug costs and reduce out-of-pocket costs for patients. This is not a proposed rule, but is an opportunity for public comment before a proposed rule is drafted. CMS is considering issuing a proposed rule on the potential model in the spring of 2019. The IPI Model would start in spring 2020 and operate for five years, until the spring of 2025. ACR requests feedback on the following items.
CMS is interested in public comments on several potential model components including
If implemented, over the course of the model, CMS plans monitor and evaluate the impact of the model on beneficiary access to drugs, program costs, and the quality of care for beneficiaries.
You can download the ANPRM from the CMS Newsroom.
The ACR opposes mandatory demonstration models in Medicare and has concerns about parts of the IPI model, while remaining committed to engaging with CMS.
The ACR is working with other patient and physician groups to understand the impact of such a model on rheumatology and other specialties that have a high utilization of Part B drugs.
The ACR will submit comments on or before December 31, 2018 with the input of the Government Affairs Committee (GAC) and Committee on Rheumatologic Care (CORC).
The ACR welcomes your feedback about this ANPRM, including specific technical concerns and suggestions that could prevent disruption of patients’ access to drugs under the proposed model. Please send your feedback to email@example.com.
View the latest rheumatology news, including press releases and public statements about current advocacy issues affecting ACR and ARHP membership in the Newsroom.
The ACR publishes a bimonthly electronic newsletter for members with the latest news and activities relating to advocacy and policy updates, practice management, insurance issues, and more.
Be sure to follow the ACR on Facebook, Twitter, and LinkedIn. ACR often interacts with lawmakers, posts pictures, circulates articles, and more. Get engaged and join the conversation.